Blog
RSS FeedPosted by Michael Wonder on 31 May 2018
Pfizer's Xalkori makes it onto Cancer Drugs Fund
31 May 2018 - NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung ...
Posted by Michael Wonder on 27 May 2018
NICE issues decision on Mylotarg, Besponsa for leukaemia
25 May 2018 - NICE has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid ...
Posted by Michael Wonder on 23 May 2018
NICE says no to Chiesi’s rare disease drug
23 May 2018 - England’s cost effectiveness watchdog NICE has published draft guidance not recommending Chiesi’s enzyme replacement therapy Lamzede ...
Posted by Michael Wonder on 17 May 2018
NICE backs Roche’s Tecentriq for pre-treated bladder cancer
17 May 2018 - Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with ...
Posted by Michael Wonder on 14 May 2018
Price cuts secure NHS place for MS drugs
14 May 2018 - NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis ...
Posted by Michael Wonder on 05 May 2018
Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs
4 May 2018 - NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on ...
Posted by Michael Wonder on 05 May 2018
Long term benefit of neuroblastoma treatment is too uncertain, says NICE
4 May 2018 - NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk ...
Posted by Michael Wonder on 30 Apr 2018
Final NICE nod for Keytruda in bladder cancer
30 April 2018 - MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment ...
Posted by Michael Wonder on 19 Apr 2018
Final NHS nod for Roche’s RoActemra
19 April 2018 - Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis within ...
Posted by Michael Wonder on 11 Apr 2018
Use of Merck's Bavencio (avelumab) on NHS supported by NICE
11 April 2018 - Draft final guidance proposes different access streams for first-line and second-line use in patients with Merkel ...
Posted by Michael Wonder on 07 Apr 2018
Roche cops another rejection from NICE
6 April 2018 - Second rebuttal from NICE in as many days. ...
Posted by Michael Wonder on 05 Apr 2018
NICE set to reject Roche's Ocrevus (ocrelizumab)
5 April 2018 - NICE has published an appraisal consultation document for ocrelizumab for the treatment of patients with relapsing ...
Posted by Michael Wonder on 03 Apr 2018
Atopic dermatitis patients to be denied NHS access to Dupixent
3 April 2018 - NICE has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis. ...
Posted by Michael Wonder on 22 Mar 2018
Psoriasis patients get NHS access to LEO Pharma’s Kyntheum
22 March 2018 - Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the ...
Posted by Michael Wonder on 20 Mar 2018
NICE rejects rare eye disease drug
20 March 2018 - Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for ...